pinoresinol diglucoside has been researched along with Constriction, Pathologic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Fu, X; Guo, J; Liang, T; Pan, R; Sun, T; Wang, L; Zhang, J; Zhang, L | 1 |
1 other study(ies) available for pinoresinol diglucoside and Constriction, Pathologic
| Article | Year |
|---|---|
Pinoresinol diglucoside (PDG) attenuates cardiac hypertrophy via AKT/mTOR/NF-κB signaling in pressure overload-induced rats.
Topics: Animals; Animals, Newborn; Aorta, Abdominal; Cardiomegaly; Constriction, Pathologic; Disease Models, Animal; Fibrosis; Inflammation; Isoproterenol; Lignans; Male; Myocytes, Cardiac; NF-kappa B; Phenylephrine; Pressure; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases; Ventricular Remodeling | 2021 |